CHRS
Coherus Oncology, Inc.
Biotechnology · Healthcare · United States
0.83
close · 2026-10-30
value
34
cheaper than peers34
quality
21
stronger fundamentals21
ranked against
Biotechnology (commercial)
value
quality
162 peerswide variation
Value inputs
| measure | company | vs peers |
| earnings yield, latest year | 172.3% | 100 |
| earnings yield, 1 year ago | 30.1% | 98 |
| price to sales | 2.52× | 85 |
| price to book | 2.11× | 69 |
| cash flow yield, 1 year ago | -15.9% | 38 |
| cash flow yield, 3 years ago | -188.0% | 8 |
| cash flow yield, latest year | -108.0% | 7 |
| earnings yield, 2 years ago | -304.8% | 7 |
| cash flow yield, 2 years ago | -136.4% | 7 |
| earnings yield, 3 years ago | -453.0% | 4 |
10 of 12 measures available
Quality inputs
| measure | company | vs peers |
| revenue growth | 39.5% | 62 |
| operating margin | -226.0% | 44 |
| debt to equity | 89.1% | 24 |
| return on equity | -178.4% | 13 |
4 of 4 measures available
Facts
| market cap | $128M |
| free cash flow | -$160.2M |
| employees | 144 |
| first trade | 2014-11-06 |
| next earnings | 2026-11-09 |
| fundamentals updated | 2026-08-14 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | 1.43 | 0.25 | -2.53 | -3.76 |
| free cash flow | -$138.5M | -$20.4M | -$174.9M | -$241.1M |
| net income | $168.0M | $28.5M | -$237.9M | -$291.8M |
| revenue | $42.2M | $26.4M | $257.2M | $211.0M |
| unusual items | $0 | -$12.6M | $0 | -$6.2M |